HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Dietary Supplement Claims Oversight Will Be “More Aggressive” – Troy

This article was originally published in The Tan Sheet

Executive Summary

FDA plans to intensify enforcement of inappropriate structure/function claims, Chief Counsel Daniel Troy asserted at the Food & Drug Law Institute educational conference April 16-17

You may also be interested in...



CFSAN Adverse Event Strategy: Will Notifying Industry Create A 2-Way Road?

CFSAN will begin sending letters to companies notifying them when an adverse event report involving one of their products has been received on or after Sept. 16

FDA’s Supplement AER System Nets $1.5 Mil. Under Ag Approps

FDA's dietary supplement adverse event monitoring system will receive $1.5 mil. in funding for FY 2002 under the 1agriculture appropriations conference report adopted by both the House and Senate

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS130091

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel